Skip to main content

Table 4 Association between characteristics of trials and statistically significant outcome or conclusions favoring the test drug: Multivariate logistic regression (first/main reports only, n = 115)

From: Association of trial registration with the results and conclusions of published trials of new oncology drugs

   Results Favor Test Drug Conclusions Favor Test Drug
Characteristic Category Favorable n/Total n (%) OR
(95% CI)
P Favorable n/Total n (%) OR
(95% CI)
P
Trial registration before publication No 34/70 (49) 1.00   46/70 (66) 1.00  
  Yes 28/45 (62) 1.11 (0.44-2.80) 0.832 34/45 (76) 1.10 (0.41-2.98) 0.854
Blinding Stringent 13/31 (42) 1.00   20/31 (65) 1.00  
  Not stringent 49/84 (58) 3.03 (1.13-8.16) 0.028 60/84 (71) 1.86 (0.69-5.05) 0.221
Sample size Natural log - 2.20 (1.40-3.45) <0.001 - 1.65 (1.09-2.51) 0.019
Comparison group Active comparator 24/51 (47) 1.00   33/51 (65) 1.00  
  Placebo 38/64 (59) 2.33 (0.89-6.07) 0.084 47/64 (73) 1.98 (0.73-5.41) 0.182
Primary efficacy outcome Survival 14/25 (56) 1.00   17/25 (68) 1.00  
  Surrogate 48/90 (53) 2.76 (0.82-9.28) 0.102 63/90 (70) 2.86 (0.80-10.18) 0.105
Sponsored No 13/27 (48) 1.00   15/27 (56) 1.00  
  Yes 49/88 (56) 1.02 (0.37-2.84) 0.965 65/88 (74) 1.94 (0.71-5.29) 0.194